Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy.

Abstract

Twelve patients with dysgerminoma of the ovary were treated with various cisplatin-based chemotherapy regimens. Chemotherapy was delivered as primary postoperative treatment in 6 patients. All of them are free of disease 18 to 180 months after initiation of chemotherapy. Six other patients received chemotherapy as part of the salvage treatment for recurrent disease. Three failures were observed: one toxic death, one primary failure, and one subsequent relapse. Three patients remain free of disease 50 to 95 months after initiation of chemotherapy. The role of chemotherapy in early- and advanced-stage dysgerminoma of the ovary is reviewed.

• Authors: S Culine, C Lhomme, J Kattan, P Duvillard, G Michel, A Gerbaulet, J P Droz
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 58 Issue 3 Pg. 344-8 (Sep 1995) ISSN: 0090-8258 [Print] United States
• PMID: 7672699 (Publication Type: Journal Article)

Chemical References

• Cisplatin

Topics

• Adult
• Aged
• Cisplatin (adverse effects, therapeutic use)
• Dysgerminoma (drug therapy, mortality, surgery)
• Female
• Humans
• Neoplasm Recurrence, Local
• Ovarian Neoplasms (drug therapy, mortality, surgery)
• Postoperative Care
• Survival Analysis